Abstract:Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal disorder caused by the deficiency of arylsulfatase A (ASA), resulting in impaired degradation of sulfatide, an essential sphingolipid of myelin. The clinical manifestations of MLD are characterized by progressive demyelination and subsequent neurological symptoms resulting in severe debilitation. The availability of therapeutic options for treating MLD is limited but expanding with a number of early stage clinical trials already in progress. In the development of therapeutic approaches for MLD, scientists have been facing a number of challenges including blood-brain barrier (BBB) penetration, safety issues concerning therapies targeting the central nervous system, uncertainty regarding the ideal timing for intervention in the disease course, and the lack of more in-depth understanding of the molecular pathogenesis of MLD. Here, we discuss the current status of the different approaches to developing therapies for MLD. Hematopoietic stem cell transplantation has been used to treat MLD patients, utilizing both umbilical cord blood and bone marrow sources. Intrathecal enzyme replacement therapy and gene therapies, administered locally into the brain or by generating genetically modified hematopoietic stem cells, are emerging as novel strategies. In pre-clinical studies, different cell delivery systems including microencapsulated cells or selectively neural cells have shown encouraging results. Small molecules that are more likely to cross the BBB can be used as enzyme enhancers of diverse ASA mutants, either as pharmacological chaperones, or proteostasis regulators. Specific small molecules may also be used to reduce the biosynthesis of sulfatides, or target different affected downstream pathways secondary to the primary ASA deficiency. Given the progressive neurodegenerative aspects of MLD, also seen in other lysosomal diseases, current and future therapeutic strategies will be complementary, whether used in combination or separately at specific stages of the disease course, to produce better outcomes for patients afflicted with this devastating inherited disorder.

Metachromatic leukodystrophy: consequences of sulphatide accumulation

Delay of myelin formation in arylsulphatase A-deficient mice

Synthetic Sulfogalactosylceramide (sulfatide) and Its Use for the Mass Spectrometric Quantitative Urinary Determination in Metachromatic Leukodystrophies

Effects of Sulfatide Accumulation on Peripheral Nerves in Metachromatic Leukodystrophy (P3-5.001)

Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy

Developing therapeutic approaches for metachromatic leukodystrophy

Identification of two novel arylsulfatase A mutations with a polymorphism as a cause of metachromatic leukodystrophy

Mannose 6-phosphate receptor-dependent endocytosis of lysosomal enzymes is increased in sulfatide-storing kidney cells

Complete Correction of Brain and Spinal Cord Pathology in Metachromatic Leukodystrophy Mice

[Metachromatic leukodystrophy (MLD) and Multiple sulphatase deficiency (MSD)]

Exploring the effect of disease causing mutations in metal binding sites of human ARSA in metachromatic leukodystrophy

Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy

The natural history and burden of illness of metachromatic leukodystrophy: a systematic literature review

Longitudinal volumetric analysis of gray matter atrophy in metachromatic leukodystrophy

Motor and psycho-cognitive clinical types in adult metachromatic leukodystrophy: genotype/phenotype relationships?

Importance of the glycosylation and polyadenylation variants in metachromatic leukodystrophy pseudodeficiency phenotype

Neurodegenerative disease after hematopoietic stem cell transplantation in metachromatic leukodystrophy

Oligomerization capacity of two arylsulfatase A mutants: C300F and P425T

Systemic inflammation and neurodegeneration in a mouse model of multiple sulfatase deficiency

Inflammation and autophagy dysfunction in metachromatic leukodystrophy: a central role for mTOR?

A systematic review on the birth prevalence of metachromatic leukodystrophy